Shanghai MicuRx Pharmaceutical Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai MicuRx Pharmaceutical Co., Ltd.

Why is Shanghai MicuRx Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of 29.42% and Operating profit at -1.97% over the last 5 years

Flat results in Sep 25

ROCE(HY) Lowest at -83.12%
DEBT-EQUITY RATIO (HY) Highest at -46.16 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -1.53%, its profits have risen by 25%

Below par performance in long term as well as near term

Along with generating -1.53% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shanghai MicuRx Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Shanghai MicuRx Pharmaceutical Co., Ltd.

4.78%

0.82

50.86%

China Shanghai Composite

16.01%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

29.42%

EBIT Growth (5y)

-1.97%

EBIT to Interest (avg)

-53.81

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.81

Sales to Capital Employed (avg)

0.15

Tax Ratio

1.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

19.51

EV to EBIT

-15.58

EV to EBITDA

-16.35

EV to Capital Employed

73.68

EV to Sales

43.29

PEG Ratio

Dividend Yield

ROCE (Latest)

-473.03%

ROE (Latest)

-124.29%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -19.44% (YoY

NET SALES(Q)

Highest at CNY 37.02 MM

OPERATING PROFIT(Q)

Highest at CNY -55.54 MM

OPERATING PROFIT MARGIN(Q)

Highest at -150.04 %

PRE-TAX PROFIT(Q)

Highest at CNY -56.64 MM

NET PROFIT(Q)

Highest at CNY -56.65 MM

EPS(Q)

Highest at CNY -0.08

-5What is not working for the Company

ROCE(HY)

Lowest at -83.12%

DEBT-EQUITY RATIO (HY)

Highest at -46.16 %

Here's what is working for Shanghai MicuRx Pharmaceutical Co., Ltd.

Net Sales

Highest at CNY 37.02 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Operating Profit

Highest at CNY -55.54 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin

Highest at -150.04 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CNY -56.64 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY -56.65 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY -0.08

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -19.44% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai MicuRx Pharmaceutical Co., Ltd.

Debt-Equity Ratio

Highest at -46.16 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio